Zynerba Pharma (ZYNE) Tops Q1 EPS by 7c

Zynerba Pharma (NASDAQ: ZYNE) reported Q1 EPS of ($0.49), $0.07 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $7.25 thousand versus the consensus estimate of $10 thousand.

Financial Outlook

Based on current operating plans, the Company expects that its existing cash and cash equivalents will fund its research and development programs and operations through 2017, which will include Phase 2 data readout for the five indications of ZYN002 and ZYN001.

For earnings history and earnings-related data on Zynerba Pharma (ZYNE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• HeartCore Enterprises, Inc. (HTCR) Misses Q2 EPS by 185c
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c